Attovia Therapeutics Inc.: Leerink Initiates Coverage on Stock After Successful IPO with Price Target of $52!
Reading Time: 3 minutes
Attovia Therapeutics (ATTO) develops complex biologics for immune-mediated diseases using its proprietary ATTOBODY platform. The research firm Leerink initiated coverage on August 31, 2026, with an "Outperform" rating and a price target of $52. After a successful IPO, the company has the financial foundation to drive clinical studies in an addressable market exceeding $2.7 billion. ATTOBODY Platform Addresses Immune Diseases Attovia Therapeutics' (ATTO) business model is based on the proprietary ATTOBODY platform, aimed at developing complex...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
